Efficacy of valganciclovir prophylaxis in kidney transplant recipients following low-dose rituximab induction therapy: a multicenter retrospective study
Clinical and Experimental Nephrology · 2025
DOI: 10.1007/s10157-024-02578-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Experimental Nephrology, 2025. Verfasst von Tomohiro Takehara und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Pulmonology, and Nephrology, Faculty of Medicine, Yamagata University, Yamagata, Japan. Hauptthemen laut MEDLINE: Kidney Transplantation, Valganciclovir, Rituximab, Cytomegalovirus Infections. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Rituximab (RIT) induction therapy is widely used for desensitization against ABO-incompatible living-donor kidney transplants (KT). However, the efficacy of valganciclovir (VGCV) prophylaxis against cytomegalovirus (CMV) disease and infection in KT recipients (KTRs) following RIT induction remains unclear. METHODS: The current multicenter retrospective study included 213 KTRs who received low-dose RIT induction between 1998 and 2021, across 6 facilities included in the Michinoku Renal Transplant Network (MRTN). VGCV dosage varied from 450 mg/day (twice weekly) to 900 mg/day (daily), with treatment durations of 3-12 months. The primary and secondary endpoints were the incidence of CMV disease and infection, respectively. RESULTS: The incidence of CMV disease was significantly higher in the VGCV group (23.5%; 16 patients) than in the non-VGCV group (5.5%; 8 patients) (p < 0.01). The incidence of CMV infection was 54.5% (79 patients) in the non-VGCV group and 48.5% (33 patients) in the VGCV group, with no significant difference (p = 0.42). In the subgroup of CMV-seronegative KTRs receiving allografts from CMV-seropositive donors (CMV IgG (D + /R-)), 18 out of 24 KTRs received VGCV prophylaxis, of whom 10 (55.6%) developed CMV disease. Within this subgroup, only 4 KTRs received VGCV with the standard protocol (900 mg daily for 6 months), and none developed CMV disease. CONCLUSION: Insufficient VGCV prophylaxis does not reduce the incidence of CMV disease in KTRs following low-dose RIT induction. Despite concerns about leukopenia due to RIT and VGCV, in KTRs with CMV IgG (D + /R-) serostatus, VGCV prophylaxis with a standard protocol may be advisable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Pulmonology, and Nephrology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
- Department of Urology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan. hnishida331@yahoo.co.jp.
- Department of Urology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
- Department of Urology, Iwate Medical University, Morioka, Iwate, Japan.
- Department of Urology, Iwate Prefectural Isawa Hospital, Oshu, Iwate, Japan.
- Department of Urology, Akita University School of Medicine, Akita, Japan.
Zitieren
APA
Takehara, T., Nishida, H., Ichikawa, K., Nawano, T., Takai, S., Fukuhara, H., Matsuura, T., Maita, S., Saito, M., Murakami, R., Hatakeyama, S., Obara, W., Saitoh, H., Ohyama, C., Habuchi, T., Watanabe, M., & Tsuchiya, N. (2025). Efficacy of valganciclovir prophylaxis in kidney transplant recipients following low-dose rituximab induction therapy: a multicenter retrospective study. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-024-02578-4
Vancouver
Takehara T, Nishida H, Ichikawa K, Nawano T, Takai S, Fukuhara H, et al. Efficacy of valganciclovir prophylaxis in kidney transplant recipients following low-dose rituximab induction therapy: a multicenter retrospective study. Clinical and Experimental Nephrology. 2025. doi:10.1007/s10157-024-02578-4
BibTeX
@article{Takehara2025,
author = {Takehara, Tomohiro and Nishida, Hayato and Ichikawa, Kazunobu and Nawano, Takaaki and Takai, Satoshi and Fukuhara, Hiroki and Matsuura, Tomohiko and Maita, Shinya and Saito, Mitsuru and Murakami, Reiichi and Hatakeyama, Shingo and Obara, Wataru and Saitoh, Hisao and Ohyama, Chikara and Habuchi, Tomonori and Watanabe, Masafumi and Tsuchiya, Norihiko},
title = {Efficacy of valganciclovir prophylaxis in kidney transplant recipients following low-dose rituximab induction therapy: a multicenter retrospective study},
journal = {Clinical and Experimental Nephrology},
year = {2025},
doi = {10.1007/s10157-024-02578-4}
}
EUVIMED